Which Healthcare ETF Is the Better Buy: Invesco’s Broad RSPH or First Trust’s Biotech FBT?

When considering healthcare ETFs for investment, two prominent options are Invesco's S&P 500 Equal Weight Health Care ETF (RSPH) and First Trust's NYSE Arca Biotechnology Index Fund (FBT). Both funds offer unique advantages and cater to different investment strategies.

RSPH provides broad healthcare exposure, tracking the entire S&P 500 equal-weight healthcare index with a focus on 60 established companies. Its lower expense ratio of 0.4% makes it an affordable choice for investors seeking diversified healthcare exposure. RSPH holds positions in well-known biotech companies such as Moderna, Illumina, and Revvity, ensuring a steady performance during market downturns.

On the other hand, FBT is a more concentrated fund, focusing exclusively on biotechnology stocks. With an expense ratio of 0.55%, FBT charges slightly higher management fees to specialize in the biotech sub-sector. The fund holds a smaller portfolio of 30 biotech companies, which can lead to significant performance swings based on FDA approvals or acquisitions. FBT's largest holdings include Natera, Illumina, and Halozyme Therapeutics, demonstrating its commitment to this high-growth sector.

Investors seeking a balanced approach to healthcare investment may find RSPH to be the more reliable option, offering steady returns and lower volatility. Conversely, those with a higher risk tolerance and a strong belief in the continued growth of the biotech industry might opt for FBT's concentrated portfolio. Ultimately, the choice between RSPH and FBT depends on an investor's risk appetite, investment horizon, and strategic focus within the healthcare sector.